Cargando…
Darunavir-Resistant HIV-1 Protease Constructs Uphold a Conformational Selection Hypothesis for Drug Resistance
Multidrug resistance continues to be a barrier to the effectiveness of highly active antiretroviral therapy in the treatment of human immunodeficiency virus 1 (HIV-1) infection. Darunavir (DRV) is a highly potent protease inhibitor (PI) that is oftentimes effective when drug resistance has emerged a...
Autores principales: | Liu, Zhanglong, Tran, Trang T., Pham, Linh, Hu, Lingna, Bentz, Kyle, Savin, Daniel A., Fanucci, Gail E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7695139/ https://www.ncbi.nlm.nih.gov/pubmed/33171603 http://dx.doi.org/10.3390/v12111275 |
Ejemplares similares
-
Unique Flap Conformation in an HIV-1 Protease with High-Level Darunavir Resistance
por: Nakashima, Masaaki, et al.
Publicado: (2016) -
Structures of Darunavir-Resistant HIV-1 Protease
Mutant Reveal Atypical Binding of Darunavir to Wide Open Flaps
por: Zhang, Ying, et al.
Publicado: (2014) -
Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021) -
Evaluation of novel protease inhibitors against darunavir‐resistant variants of HIV type 1
por: Inoue, Mari, et al.
Publicado: (2016) -
Effects of drug-resistant mutations on the dynamic properties of HIV-1 protease and inhibition by Amprenavir and Darunavir
por: Yu, Yuqi, et al.
Publicado: (2015)